News

Artelo Biosciences Unveils Promising ART12.11 Data for CBD Formulation

Artelo Biosciences Unveils Promising ART12.11 Data for CBD Formulation

Exciting Developments in CBD Formulations by Artelo Biosciences

Artelo Biosciences, Inc. (Nasdaq: ARTL), a notable player in the pharmaceutical realm focusing on lipid-signaling pathways, has announced important nonclinical findings on its innovative tablet formulation, ART12.11. This proprietary composition combines cannabidiol (CBD) with tetramethylpyrazine (TMP), addressing various medical needs, including pain management and neurological conditions.

Significant Findings Presented at Key Conference

These groundbreaking results were shared by Professor Saoirse O’Sullivan, Vice President of Translational Science at Artelo, during a premier event, the International Medical Cannabis Conference (IMCCB-25). The conference, which facilitated discussions on cannabis-based therapies, highlighted the potential of ART12.11 as a promising alternative to existing CBD solutions, particularly Epidiolex, the only FDA-approved CBD therapy available today.

Comparative Analysis with Epidiolex

In studies conducted on canines, the analysis revealed that ART12.11's tablet formulations achieved CBD and metabolite exposure levels equivalent to or exceeding those of Epidiolex. These findings bolster the notion that ART12.11 could serve as a more accessible and efficient formulation for patients in need of CBD therapies.

Benefits of Solid-dose Formulations

The transition from liquid to solid formulations like ART12.11 presents several notable advantages, such as enhanced stability, ease of dosing, and cost-effectiveness. Furthermore, the cocrystallization method used in ART12.11's development significantly improves drug solubility and bioavailability, tackling common challenges faced by current CBD formulations.

Future Prospects for ART12.11

Andrew Yates, Senior Vice President and Chief Scientific Officer at Artelo, expressed optimism about the results, emphasizing how ART12.11 stands out as a commercially viable product. Its unique formulation not only boasts better pharmacokinetics and efficacy but also offers a scalable and economically feasible method to produce CBD in tablet form, which is crucial for broader therapeutic applications.

Ongoing Development and Human Studies

Artelo is dedicated to advancing ART12.11, with plans to further investigate its potential in human studies to ensure its safety and effectiveness. The proprietary nature of ART12.11, combined with a valid U.S. patent until 2038, positions it favorably in a competitive market.

About Artelo Biosciences

Artelo Biosciences is at the forefront of developing therapeutics that effectively modulate lipid-signaling pathways. Its portfolio aims to tackle critical medical challenges across a range of conditions including cancer, pain, and inflammation. With a team of seasoned executives and top-tier researchers, Artelo applies rigorous scientific methodologies to create impactful therapies for patients.

Additional Insights on IMCCB-25

The IMCCB-25 conference seeks to foster a better understanding of cannabis and cannabinoid-based therapies among healthcare professionals. It focuses on sharing the latest research, therapeutic guidelines, and practical applications of cannabis, ensuring that modern medical practices align with ongoing advancements in the field.

Frequently Asked Questions

What is ART12.11?

ART12.11 is a unique cocrystal formulation of cannabidiol (CBD) and tetramethylpyrazine (TMP) developed by Artelo Biosciences to enhance therapeutic options for patients.

How does ART12.11 compare to Epidiolex?

Studies indicate that ART12.11 demonstrates comparable or superior pharmacokinetics to Epidiolex, potentially offering an advantageous alternative to existing CBD treatments.

What advantages does a solid-dose formulation offer?

Solid-dose formulations like tablets provide improved stability, easier dosing, lower production costs, and enhanced patient compliance compared to liquid forms.

What are the future plans for ART12.11?

Artelo intends to advance ART12.11 into human studies to further assess its safety and efficacy while exploring its commercial viability.

Who are the key players in Artelo Biosciences?

Artelo's leadership comprises experienced biopharmaceutical executives and distinguished researchers committed to solving unmet medical needs across various conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Africa Tech Festival 2026: A Digital Turning Point

Updated Category News Views 96

Setting the Stage for Digital Advancement in Africa Come mid-November, Cape Town's gonna be buzzing with the clatter of tech titans and financial honchos making their annual pilgrimage to the Africa Tech Festival. This ain't just a conference shindig—with names like Naspers, MTN, Meta, and Amazon on the docket, it's a darn convention shaping the continent's future...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 84

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 421

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 80

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 103

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Pine Tree Bets Big on Tulsa Hills Shopping Center

Updated Category News Views 85

Pine Tree's Latest Move in Retail Real Estate Ya ever watch a company make a move so aligned with its playbook that it feels like a script straight outta the boardroom? That's Pine Tree with its recent snag of Tulsa Hills Shopping Center for a cool $108 million. This ain't just any retail spot; it's a bustling hub nestled within the posh outskirts of Jenks, Oklahoma....

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 59

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 59

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading

Top 5 Most Recently Viewed Articles

Citi Raises Price Target for Blackstone Amid Encouraging Outlook

Updated Category News Views 131

Citi's Updated Outlook on Blackstone Recently, Citi revisited its financial forecast for The Blackstone Group (NYSE: BX), adjusting the price target upward from $157.00 to $170.00 while maintaining a Neutral stance on the stock. This update follows the company's impressive third-quarter performance, which saw Blackstone's stock rise by 6.3% post-earnings announcement....

Continue Reading
JAB's Strategic Acquisition of Mondelez Shares in JDE Peet's

Updated Category News Views 92

JAB's Significant Move in the Coffee Industry In a strategic and noteworthy development, JAB has made headlines by agreeing to acquire a substantial share package from Mondelez, focusing on Dutch coffee giant JDE Peet's. This major transaction amounts to approximately €2.2 billion, or about $2.4 billion. JAB intends to purchase 86 million shares at a price of €25.10...

Continue Reading
Urgent Update for DXC Technology Company Investors

Updated Category News Views 272

DXC Technology Company (NYSE: DXC) found itself in hot water back in 2024 when shareholders raised hell over alleged falsehoods that inflated stock prices. The Rosen Law Firm rolled out a class action lawsuit aimed at those who bought shares during what they dubbed the Class Period—a time rife with questionable operational claims from DXC's brass. Allegations Surface:...

Continue Reading
Investigation Launched: National Grid Faces Legal Scrutiny

Updated Category News Views 283

Bragar Eagel & Squire, P.C. Initiates Investigation Bragar Eagel & Squire, P.C., a well-regarded law firm known for advocating for investors, has begun an investigation surrounding concerns related to National Grid plc (NYSE: NGG). This inquiry primarily aims to assist stockholders who may have experienced losses while owning shares of National Grid. The firm invites...

Continue Reading
Oil & Gas Sector Trends: Path to 8.79 Trillion Growth

Updated Category News Views 223

Oil & Gas Market Growth and Projections The global oil and gas market has positioned itself for remarkable expansion. With estimates currently valuing the market at approximately USD 6.10 trillion, projections suggest it could soar to around USD 8.79 trillion by 2034. This growth translates to a compound annual growth rate (CAGR) of 3.72% between 2025 and 2034. Notably,...

Continue Reading